Loading
The whole lifecycle, verified against the filings.
Definitive (DA signed)
Summed over all 2 filed.
No dated vote for these deals is on file with us yet — our record, not the companies' calendars.
More equity than the headline, over 1 of 2 measured.
Too few quarters in this view to draw a cadence.
A definitive agreement is signed and the vote is still ahead, so the redemption right survives to it.
The list is grouped by lifecycle stage and the sort orders rows inside a stage: a vote that has already passed and one still ahead are not the same list. An announced deal is not a closed deal — 1 of the combinations in our record were terminated. A premium to trust is a selling point, not a buying point — and once a vote has passed there is no redemption right left to price against. Every stage, target and figure here is read from the SEC filing that stated it; where a figure is missing it is missing from our record, and the page says so rather than estimating one.
0 of 2 deals in this view carry a dated vote or a stated close period. Where the Vote column is empty, the filings we hold state neither — that is a gap in our record, not a claim that the parties have no timetable.
Sorted inside each stage.
| RFAMRF Acquisition III | HCC Healthcare Pte. Ltd. | Healthcare | $500M | Jul 9, 2026 | $9.98 | +1.5% | Definitive (DA signed) | 7171 | HCC Healthcare Pte. Ltd. is a Singapore-incorporated exempt private company that operates through consolidated subsidiaries in Taiwan, forming one of the largest integrated medical and long-term care platforms on the island. The group traces its origins to a single obstetrics clinic founded by Dr. Hsiao Chung-Cheng, and over more than three decades of clinical heritage has evolved into a comprehensive healthcare ecosystem spanning Northern, Central, and Southern Taiwan. On a pro forma combined basis, the network encompasses more than 120 long-term care facilities and over 9,000 licensed beds, including one of the largest caregiving institutions in Taiwan with more than 1,300 beds, operated under a distinctive "hospital-within-an-eldercare-institution" ecosystem model. The group also provides community- and home-based case management for over 7,000 individuals, concentrated in Northern Taiwan, a region representing roughly one-third of the country's population. Its service offerings span medical care, long-term care, caregiver support, rehabilitation, hemodialysis, pharmaceutical services, infection control, nutritional support, social work, medical transportation, consumables procurement, and medical education and consulting. The company is organized around four strategic business segments: a regional healthcare network anchored by Hsiao Chung-Cheng Hospital (a Grade A NHI-accredited facility), an AI technology platform, a smart long-term care and pharmacy chain operated through Fu Ze Health (a TriHealth subsidiary), and TriHealth Enterprise, which serves as the operational backbone for centralized procurement, logistics, and a long-term care transport fleet. HCC's AI platform leverages an exclusive partnership with Taiwan's National Center for High-Performance Computing for federated learning across all facilities, alongside robotic pharmacy dispensing, a real-time digital twin operational model, predictive analytics for chronic disease management, AI-powered clinical documentation, and a franchise engine designed for capital-efficient site rollouts. The group's strategic growth roadmap centers on four priorities: deploying its proprietary AI platform integrating spatial intelligence and multimodal clinical data, expanding into Japan leveraging existing infrastructure and Japan's regenerative medicine regulatory framework, developing cross-sector partnerships with fitness and wellness operators for preventive and chronic disease care pathways, and accelerating investment in precision and regenerative medicine including AI-driven biomarker profiling. HCC Healthcare is led by Chief Executive Officer Jack Hsiao, while the SPAC side is headed by Tse Meng Ng, CEO of RF Acquisition Corp III, who also serves as Chief Advisor of DH Wealth Management and played a pivotal role in structuring and executing the transaction. The Singapore holding entity was formally incorporated on September 9, 2025, though the underlying operating group claims over five decades of healthcare heritage. The business combination with RF Acquisition Corp III (Nasdaq: RFAM) values HCC Healthcare at approximately US$500 million on a fully diluted equity basis, with a per-share reference value of US$10.00 following a pre-closing recapitalization. The deal is expected to close in the fourth quarter of 2026, subject to shareholder approvals, effectiveness of a Form F-4 registration statement, and Nasdaq or NYSE listing approval. Certain HCC shareholders and the SPAC founder Alfa 30 have signed voting support and lock-up agreements of up to six months post-closing, and the post-closing board will comprise seven directors, six from HCC and one from Alfa 30 Limited. EarlyBirdCapital is advising RF Acquisition, while K&L Gates and PricewaterhouseCoopers Legal are serving as U.S. and Taiwan counsel respectively to HCC Healthcare, with Bedrock Investment acting as strategic consultant to the company. HCC Healthcare is pursuing a SPAC merger rather than a traditionalmore ▾less ▴ |